Core Viewpoint - The company,药捷安康-B (02617), experienced a decline of over 3%, trading at 109 HKD with a transaction volume of 23.576 million HKD following the announcement of a share placement [1] Group 1: Share Placement Details - The company announced a placement of 2.1 million shares, which represents approximately 0.69% of the enlarged H shares and about 0.53% of the total issued shares [1] - The placement price is set at 92.85 HKD per share, reflecting a discount of approximately 17.98% compared to the closing price of 113.2 HKD on January 13 [1] Group 2: Fund Utilization - The expected net proceeds from the placement are approximately 190 million HKD, with around 60% allocated for funding clinical trials of the core product Tinengotinib for the treatment of cholangiocarcinoma (CCA) in China, as well as for the development of other indications [1] - About 30% of the proceeds will be used for the research and development of other products, including TT-00973, TT-01488, and other molecules [1] - Approximately 10% of the funds will be directed towards working capital and general corporate purposes [1]
港股异动 | 药捷安康-B(02617)跌超3% 拟折让近18%配股 净筹1.9亿港元